Treatment of SCCVII tumors with systemic chemotherapy and Interleukin-12 gene therapy combination.
Cyclophosphamide and Interleukin-12 (IL-12) have been successfully used in clinical trials for treating malignancies. In this study, we explore the coadministration of cyclophosphamide and IL-12 plasmid DNA followed by electroporation for treating SCCVII in mice. Cyclophosphamide, IL-12 plasmid DNA, or a combination of both was injected intramuscularly in mice bearing SCCVII tumors. The tumor growth, survival, cytokine expression, cytotoxic T lymphocyte activity, and vascular density were analyzed. Coadministration of cyclophosphamide and IL-12 plasmid DNA via electroporation delays tumor growth and increases survival in mice. This combination therapy has great potential to be translated to a clinical setting for treating malignancies.
Torrero
Marina
M
Department of Comparative Biomedical Sciences, Louisiana State University, Baton Rouge, LA, USA.
Li
Shulin
S
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004274:DNA, Recombinant / Q000008:administration & dosage / Q000235:genetics; D053672:Electrochemotherapy / Q000379:methods; D015316:Genetic Therapy / Q000379:methods*; D007371:Interferon-gamma / Q000096:biosynthesis; D018664:Interleukin-12 / Q000096:biosynthesis / Q000235:genetics*; D051379:Mice; D008809:Mice, Inbred C3H; D010957:Plasmids / Q000008:administration & dosage / Q000235:genetics; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D018906:Antineoplastic Agents, Alkylating; D004274:DNA, Recombinant; D011994:Recombinant Proteins; D018664:Interleukin-12; D007371:Interferon-gamma; D003520:Cyclophosphamide